This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Balzarini, J Articles by De Clercq, E Search for Related Content PubMed PubMed Citation Articles by Balzarini, J Articles by De Clercq, E

 Previous Article  |  Next Article 

J Virol. 1993 September; 67(9): 5353-5359

Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy.

Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium.

ABSTRACT

Human immunodeficiency virus type 1 (HIV-1)-infected CEM cells were treated by the HIV-1-specific inhibitors bis-heteroarylpiperazine (BHAP), 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1 H)-on e (TIBO) R82913, nevirapine, and the N3-methylthymine derivative of [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) (TSAO-m3T), as single agents or in combination, at escalating concentrations. When used individually, the compounds led to the emergence of drug-resistant virus strains within two to five subcultivations. The resulting strains were designated HIV-1/BHAP, HIV-1/TIBO, HIV-1/Nev, and HIV-1/TSAO-m3T, respectively. The mutant viruses showed the following amino acid substitutions in their reverse transcriptase (RT): Leu-100-->Ile for HIV-1/BHAP; Lys-103-->Asn for HIV-1/TIBO; Val-106-->Ala for HIV-1/Nev; and Glu-138-->Lys for HIV-1/TSAO-m3T. Both the Tyr-181-->Cys and Val-106-->Ala mutations were found in another mutant emerging following treatment with nevirapine at escalating concentrations. The BHAP-resistant virus remained fully sensitive to the inhibitory effects of nevirapine and TSAO-m3T, whereas the TSAO-m3T-resistant virus remained fully sensitive to the inhibitory effects of nevirapine and BHAP. When different pairs of nonnucleoside RT inhibitors (i.e., BHAP plus TSAO-m3T, nevirapine plus TSAO-m3T, TIBO plus TSAO-m3T, nevirapine plus TIBO, and BHAP plus nevirapine) were used, resistant virus emerged as fast as with single-drug therapy. In all cases the Tyr-181-->Cys mutation appeared; the virus showed markedly reduced sensitivity to all HIV-1-specific inhibitors but retained sensitivity to 2',3'-dideoxynucleoside analogs such as zidovudine, ddC, and ddI. Our findings argue against simultaneous combination of two different nonnucleoside RT inhibitors that are unable to inhibit HIV-1 mutant strains containing the Tyr-181-->Cys mutation when administered as single drugs.

This article has been cited by other articles:

• Stevens, M., Pannecouque, C., De Clercq, E., Balzarini, J. (2003). Inhibition of Human Immunodeficiency Virus by a New Class of Pyridine Oxide Derivatives. Antimicrob. Agents Chemother. 47: 2951-2957 [Abstract] [Full Text]  
• Shen, L., Shen, J., Luo, X., Cheng, F., Xu, Y., Chen, K., Arnold, E., Ding, J., Jiang, H. (2003). Steered Molecular Dynamics Simulation on the Binding of NNRTI to HIV-1 RT. Biophys. J 84: 3547-3563 [Abstract] [Full Text]  
• Buckheit, R. W. Jr., Watson, K., Fliakas-Boltz, V., Russell, J., Loftus, T. L., Osterling, M. C., Turpin, J. A., Pallansch, L. A., White, E. L., Lee, J.-W., Lee, S.-H., Oh, J.-W., Kwon, H.-S., Chung, S.-G., Cho, E.-H. (2001). SJ-3366, a Unique and Highly Potent Nonnucleoside Reverse Transcriptase Inhibitor of Human Immunodeficiency Virus Type 1 (HIV-1) That Also Inhibits HIV-2. Antimicrob. Agents Chemother. 45: 393-400 [Abstract] [Full Text]  
• Bazmi, H. Z., Hammond, J. L., Cavalcanti, S. C. H., Chu, C. K., Schinazi, R. F., Mellors, J. W. (2000). In Vitro Selection of Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase That Decrease Susceptibility to (-)-beta -D-Dioxolane-Guanosine and Suppress Resistance to 3'-Azido-3'-Deoxythymidine. Antimicrob. Agents Chemother. 44: 1783-1788 [Abstract] [Full Text]  
• Buckheit, R. W. Jr., White, E. L., Fliakas-Boltz, V., Russell, J., Stup, T. L., Kinjerski, T. L., Osterling, M. C., Weigand, A., Bader, J. P. (1999). Unique Anti-Human Immunodeficiency Virus Activities of the Nonnucleoside Reverse Transcriptase Inhibitors Calanolide A, Costatolide, and Dihydrocostatolide. Antimicrob. Agents Chemother. 43: 1827-1834 [Abstract] [Full Text]  
• Fujiwara, T., Sato, A., El-Farrash, M., Miki, S., Abe, K., Isaka, Y., Kodama, M., Wu, Y., Chen, L. B., Harada, H., Sugimoto, H., Hatanaka, M., Hinuma, Y. (1998). S-1153 Inhibits Replication of Known Drug-Resistant Strains of Human Immunodeficiency Virus Type 1. Antimicrob. Agents Chemother. 42: 1340-1345 [Abstract] [Full Text]  
• Witvrouw, M., Arranz, M. E., Pannecouque, C., Declercq, R., Jonckheere, H., Schmit, J.-C., Vandamme, A.-M., Diaz, J. A., Ingate, S. T., Desmyter, J., Esnouf, R., Van Meervelt, L., Vega, S., Balzarini, J., De Clercq, E. (1998). 1,1,3-Trioxo-2H,4H-Thieno[3,4-e][1,2,4]Thiadiazine (TTD) Derivatives: a New Class of Nonnucleoside Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Inhibitors with Anti-HIV-1 Activity. Antimicrob. Agents Chemother. 42: 618-623 [Abstract] [Full Text]  
• Esnouf, R. M., Ren, J., Hopkins, A. L., Ross, C. K., Jones, E. Y., Stammers, D. K., Stuart, D. I. (1997). Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proc. Natl. Acad. Sci. USA 94: 3984-3989 [Abstract] [Full Text]  
• Balzarini, J., Pelemans, H., Karlsson, A., De Clercq, E., Kleim, J.-P. (1996). Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors. Proc. Natl. Acad. Sci. USA 93: 13152-13157 [Abstract] [Full Text]